Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor

H Nar1, K Werle, M M Bauer

  • 1Department of Medicinal Chemistry, Boehringer Ingelheim Pharma KG, Biberach, Germany. herbert.nar@bc.boehringer-ingelheim.com

Journal of Molecular Biology
|September 29, 2001
PubMed

Insights

The crystal structure of human macrophage elastase (MMP-12) complexed with an inhibitor reveals its active site. This structural insight aids in designing targeted therapies for emphysema and other inflammatory lung diseases.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Pharmacology

Background:

  • Human macrophage elastase (MMP-12) is implicated in inflammatory processes, tissue remodeling, and particularly in the pathogenesis of emphysema.
  • Its role in elastin destruction within the lung alveolar wall makes MMP-12 a significant therapeutic target.

Purpose of the Study:

  • To determine the crystal structure of the catalytic domain of MMP-12.
  • To elucidate the binding mode of the hydroxamic acid inhibitor CGS27023A.
  • To provide a structural basis for the design of potent and selective MMP-12 inhibitors.

Main Methods:

  • X-ray crystallography was used to determine the structure of MMP-12 in complex with CGS27023A.
  • Analysis of the enzyme-inhibitor interactions and the active site architecture.

Main Results:

  • The crystal structure reveals the typical matrix metalloproteinase fold with bound zinc and calcium ions.
  • MMP-12 possesses a large S1'-specificity pocket, similar to MMP-3, MMP-8, and MMP-13.
  • The inhibitor CGS27023A binds bidentately to the catalytic zinc ion, forming hydrogen bonds and occupying the specificity pocket.

Conclusions:

  • The determined structure provides crucial insights into MMP-12's active site and substrate-binding characteristics.
  • Understanding the enzyme's structural features, including loop flexibility, facilitates the rational design of novel therapeutic agents.
  • This work supports the development of targeted inhibitors for treating MMP-12-related diseases like emphysema.